Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Finding the right unprofitable companies is difficult, which is why we started StockStory — to help you navigate the market. Keeping that in mind, here is one unprofitable company with the potential to become an industry leader and two best left off your radar.
Two Stocks to Sell:
Enovis (ENOV)
Trailing 12-Month GAAP Operating Margin: -45.1%
With a focus on helping patients regain or maintain their natural motion, Enovis (NYSE:ENOV) develops and manufactures medical devices for orthopedic care, from injury prevention and pain management to joint replacement and rehabilitation.
Why Are We Bearish on ENOV?
- Sales stagnated over the last five years and signal the need for new growth strategies
- Earnings per share fell by 9.5% annually over the last five years while its revenue was flat, showing each sale was less profitable
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
Enovis is trading at $20.69 per share, or 5.6x forward P/E. To fully understand why you should be careful with ENOV, check out our full research report (it’s free).
AdaptHealth (AHCO)
Trailing 12-Month GAAP Operating Margin: -5%
With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ:AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders.
Why Is AHCO Risky?
- Annual sales declines of 2.7% for the past two years show its products and services struggled to connect with the market during this cycle
- Falling earnings per share over the last five years has some investors worried as stock prices ultimately follow EPS over the long term
- Low returns on capital reflect management’s struggle to allocate funds effectively, and its shrinking returns suggest its past profit sources are losing steam
AdaptHealth’s stock price of $6.02 implies a valuation ratio of 5.3x forward EV-to-EBITDA. Read our free research report to see why you should think twice about including AHCO in your portfolio.
One Stock to Buy:
Rocket Lab (RKLB)
Trailing 12-Month GAAP Operating Margin: -29.1%
Becoming the first private company in the Southern Hemisphere to reach space, Rocket Lab (NASDAQ:RKLB) offers rockets designed for launching small satellites.
Why Should You Buy RKLB?
- Annual revenue growth of 53.4% over the past two years was outstanding, reflecting market share gains this cycle
- Cash-burning tendencies have improved over the last five years, showing it could become financially independent one day
- Rising returns on capital show the company is starting to reap the benefits of its past investments
At $52.41 per share, Rocket Lab trades at 3,007x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.